期刊文献+

胰岛素受体底物在乳腺发育和恶性转化中的作用 被引量:1

Role of insulin receptor substrates in the development and oncogenic transformation of mammary gland
下载PDF
导出
摘要 胰岛素受体底物(insulin receptor substrates,IRSs)家族是胰岛素受体(insulin receptor,IR)、胰岛素样生长因子-1受体(insulin like growth-1 receptor,IGF-1R)酪氨酸蛋白激酶的主要细胞内底物,主要介导细胞对胰岛素、胰岛素样生长因子-1、白介素、干扰素、肿瘤坏死因子等多种细胞因子的反应。作为结合蛋白,它们通过连接并传递从上游的激活子到下游的效应器之间的信号,从而调节细胞正常的生长、代谢、生存与分化。在胰岛素受体底物家族接受并应答的众多细胞外信号中,大部分是与乳腺发育相关的关键信号,该蛋白在乳腺细胞中的表达是否正常决定乳腺细胞是正常发育还是恶性转化。 The family of insulin receptor substrates (IRSs) ark important intracellular substrates for tyrosine protein kinase of insulin receptor and insulin-like growth factor receptor, which mediate the responses of the cells to insulin, insulin-like receptor growth-1 receptor, interleukins, interferons, and tumor necrosis factor. IRSs act as binding proteins that connect and transduce the biological signals from up-stream activators to down-stream effectors, so as to regulate the normal growth, metabolism, survival and differentiation of the cells. The family of IRSs responds to a lot of extracellular signals, most of which are the key signals for mammogenesis. IRSs play important roles in physiological development and oncogenic transformation of mammary gland cells, and the later leads to the carcinogenesis of breast cancer.
出处 《国际病理科学与临床杂志》 CAS 2008年第6期496-499,共4页 Journal of International Pathology and Clinical Medicine
基金 国家自然科学基金(30872617)~~
关键词 胰岛素受体底物 乳腺发育 恶性转化 乳腺癌 insulin receptor substrates mammogenesis oncogenic transformation breast
  • 相关文献

参考文献27

  • 1Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway [J]. Curt Pharm Des, 2007,13(7) :663-669.
  • 2Dearth RK, Cui X, Kim H J, et al. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2[ J]. Cell Cycle, 2007,6(6) :705-713.
  • 3Rother KI, Accili D. Role of insulin receptors and IGF receptors in growth and development [ J ]. Pediatr Nephrol, 2000,14 (7) :558- 561.
  • 4Sun X J, Rnthenberg P, Kahn CR, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein [ J ]. Nature, 1991,352 (6330) :73-77.
  • 5Sesti G, Federici M, Hribal ML, et al. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders [ J ]. FASEB J, 2001, 15 (12) :2099-2111.
  • 6Kaburagi Y, Okochi H, Satoh S, et al. Role of IRS and PHIP on insulin-induced tyrosine phosphorylation and distribution of IRS proteins[J]. Cell Struct Funct, 2007,2( 1 ) :69-78.
  • 7Bjornholm M, He AR, Attersand A, et al. Absence of functional insulin receptor substrate-3 ( IRS-3 ) gene in humans [ J ]. Diabetologia, 2002,45 ( 12 ) : 1697-1702.
  • 8Cuevas EP, Escribano O, Chiloeches A, et al. Role of insulin receptor substrate-4 in IGF-I-stimulated HEPG2 proliferation [ J ]. J Hepatol, 2007,46 ( 6 ) : 1089-1098.
  • 9Cai D, Dhe-Paganon S, Melendez PA, et al. Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5 [ J ]. J Biol Chem, 2003, 278(28):25323-25330.
  • 10White MF. IRS proteins and the common path to diabetes[J]. Am J Physiol Endocrinol Metab, 2002,283 (3) :E413-422.

同被引文献21

  • 1Mustain WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes current opinion in endocrinology[J]. Curr Opin Endocrinol Diabetes Obes, 2011, 18 (1):75-82.
  • 2Evers BM. Neurotensin and growth of normal and neoplastic tissues[J]. Peptides, 2006, 27(10):2424-2433.
  • 3Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools[J]. Peptides, 2006, 27(10):2445-2460.
  • 4Alshoukr F, Prignon A, Brans L, et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors[J]. Bioconjug Chem, 2011, 22(7):1374-1385.
  • 5Zhang K, An R, Gao Z, et al. Radionuclide imaging of small- cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13[J]. Nucl Med Biol, 2006, 33(4):505-512.
  • 6Heakal Y, Kester M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells[J]. Mol Cancer Res, 2009, 7(5):724-734.
  • 7Myers RM, Shearman JW, Kitching MO, et al. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors[J]. ACS Chem Biol, 2009, 4(7):503- 525.
  • 8Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers[J]. Biochimie, 2011, 93(9):1369-1378.
  • 9Wang JG, Li NN, Li HN, et al. Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-I and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1 [J]. Neuropeptides, 2011, 45(2):151-156.
  • 10Mazella J. Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking? [J]. Cell Signal, 2001, 13(1):1-6.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部